PLOS Medicine publishes research and commentary of general interest with clear implications for patient care, public policy or clinical research agendas.
Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.
*To whom correspondence should be addressed. E-mail: email@example.com
The authors declare that they have no competing interests.
How Tumor Cells Acquire Resistance to Kinase Inhibitors
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
We want your feedback. Do these subject areas make sense for this article? If not, click the flag
next to the incorrect subject area and we will review it. Thanks for your help!
Ambra 2.10.14 Managed Colocation provided by Internet Systems Consortium.
Send us feedback
Help using this site